A5045279412- Chronic Obstructive Pulmonary Disease (COPD) Research
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Asthma and respiratory diseases
- Inhalation and Respiratory Drug Delivery
- Pneumocystis jirovecii pneumonia detection and treatment
- HIV/AIDS drug development and treatment
- Biochemical and Molecular Research
- Respiratory and Cough-Related Research
- Microfluidic and Capillary Electrophoresis Applications
- Innovative Microfluidic and Catalytic Techniques Innovation
- HIV Research and Treatment
- Pharmaceutical studies and practices
- Cystic Fibrosis Research Advances
- IL-33, ST2, and ILC Pathways
- Computational Drug Discovery Methods
- RNA Interference and Gene Delivery
- Microfluidic and Bio-sensing Technologies
- Synthetic Organic Chemistry Methods
- PI3K/AKT/mTOR signaling in cancer
- 3D Printing in Biomedical Research
- Pneumonia and Respiratory Infections
GlaxoSmithKline (United Kingdom)
2005-2021
GlaxoSmithKline (India)
2019
Babraham Institute
2019
Hammersmith Medicines Research
2019
System Simulation (United Kingdom)
2018
Age UK
2017
Laboratoire de Synthèse Organique
2004
Centre National de la Recherche Scientifique
2002-2003
Nantes Université
2003
While current therapies reduce symptoms in chronic obstructive pulmonary disease (COPD) patients, substantial unmet need remains and novel treatments are highly desired. Phosphoinositide 3-kinase δ (PI3Kδ) is a lipid kinase specifically expressed leucocytes involved their recruitment activation. This study evaluated the safety, pharmacokinetics (PK) dose-response characteristics of inhaled GSK2269557, PI3Kδ inhibitor, moderate-to-severe COPD patients with stable disease.In this randomised,...
Phosphoinositide 3-kinase <i>δ</i> (PI3K<i>δ</i>) is a lipid kinase involved in leukocyte recruitment and activation. Activation of PI3K<i>δ</i> has been linked to airway inflammation asthma pathogenesis. This randomized, double-blind, placebo-controlled, crossover study investigated the efficacy, safety, tolerability, pharmacokinetics inhibitor, nemiralisib (GSK2269557), patients with persistent, uncontrolled asthma. Patients (<i>n</i> = 50) received once-daily inhaled (1000 <i>µ</i>g) or...
Abstract Why is GlaxoSmithKline (GSK) interested in Microsystems Technology (MST) and how can MST be utilised organic synthesis biological screening for lead optimisation? The highly competitive world of the drug market forces pharmaceutical companies to undertake expensive searches safe effective leads. Although industrialisation high‐throughput implementation traditionally scaled technology has served increase individual productivity medicinal chemist industry, this still insufficient...
Nemiralisib (GSK2269557), a potent inhaled inhibitor of phosphoinositide 3-kinase <i>δ</i> (PI3K<i>δ</i>), is being developed for the treatment respiratory disorders including chronic obstructive pulmonary disease. Determining pharmacokinetic (PK) and pharmacodynamic (PD) responses drugs early during drug development key to informing appropriate dose preferred regimen in patients. We set out measure PD changes induced sputum combination with concentrations plasma bronchoalveolar lavage (BAL)...
This study evaluated the safety and efficacy of inhaled nemiralisib, a phosphoinositide 3-kinase δ (PI3Kδ) inhibitor, in patients with an acute exacerbation chronic obstructive pulmonary disease (COPD).In this double-blind, placebo-controlled study, 126 (40-80 years post-bronchodilator forced expiratory volume 1 sec (FEV1) ≤80% predicted (previously documented)) were randomized 1:1 to once daily nemiralisib (1 mg) or placebo for 84 days, added standard care. The primary endpoint was specific...
Tat is a regulatory HIV‐1 protein, which has the particularity to be secreted very early by HIV‐infected cells. The extra cellular roles of are suspected main cause maintenance reservoirs cells and failure actual AIDS therapies eradicate HIV. This study describes rationale used design molecules that bind target area containing an hydrophobic pocket identified in 2D‐NMR structure Tat. Molecules were synthesized derivative named TDS2 was shown inhibitor. Fluorescence revealed binds area,...
The Mini Spacer has been developed for use with Ventolin(®) metered dose inhalers (MDIs) to improve accessibility affordable spacers in developing countries. To ensure patient safety is not compromised if the used off-label fluticasone propionate (FP) or salmeterol/FP combination (SFC) MDIs (currently recommended), this study compared systemic exposure of FP and salmeterol following delivery SFC Aerochamber Plus(®) spacer (Aerochamber).This was an open-label, randomized, single dose,...
During the last decade, GlaxoSmithKline Pharmaceuticals (GSK) has carried out much of seminal work in area micro fluidics and flow assay for lead optimisation. It pioneered built an in-house fluidic system drug discovery. The huge diverse advantages this approach come from its miniaturised nature scale, which makes it easily automatable. As a result allows greater control over heat mass transfer, along with lower consumption reagents (both chemical biological) solvents, less waste generation...
<b>Introduction:</b> GSK2269557 was investigated in a single centre, three part, double blind (charcoal open-label), placebo controlled trial healthy subjects following inhaled delivery. Safety, tolerability and plasma PK of (100 200 µg) repeat (200 µg for 10 Days) doses were investigated, including an additional cross-over phase dosing with without charcoal (oral suspension). <b>Results:</b> Adverse Events (AEs) very low total 2 AEs out the 30 subjects, not deemed drug related or resulted...